Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Mar 10;100(5):680-3.
doi: 10.1038/sj.bjc.6604940. Epub 2009 Feb 17.

Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours

S M Tovey  1 , S Brown, J C Doughty, E A Mallon, T G Cooke, J Edwards
Affiliations

Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours

S M Tovey et al. Br J Cancer. .

Abstract

We present a retrospective analysis on a cohort of low-grade, node-negative patients showing that human epidermal growth factor receptor 2 (HER2) status significantly affects the survival in this otherwise very good prognostic group. Our results provide support for the use of adjuvant trastuzumab in patients who are typically classified as having very good prognosis, not routinely offered standard chemotherapy, and who as such do not fit current UK prescribing guidelines for trastuzumab.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan–Meier curves for HER2 status. Survival curves showing cumulative survival differences (end point=breast cancer-specific survival) between patients positive or negative for HER2. P-value represents log-rank testing of the difference in cumulative survival.
See this image and copyright information in PMC

References

    1. Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KPH, Hartwick RW, Hanna W, Lickley L, Wilkinson R, Qizilbash A, Ambus U, Lipa M, Weizel H, Katz A, Baida M, Mariz S, Stoik G, Dacamara P, Strongitharm D, Geddie W, McCready D (1998) neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J Clin Oncol 1340–1349 - PubMed
    1. Bartlett J, Mallon E, Cooke T (2003) The clinical evaluation of HER-2 status: which test to use? J Pathol 199: 411–417 - PubMed
    1. Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM, Huntsman D, Olivotto IA, Nielsen TO, Gelmon K (2008) Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 26: 5697–5704 - PubMed
    1. Harbeck N, Ross JS, Yurdseven S, Dettmar P, Polcher M, Kuhn W, Ulm K, Graeff H, Schmitt M (1999) HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer. Int J Oncol 14: 663–671 - PubMed
    1. Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkanen L, Turpeenniemi-Hujanen T, Von Smitten K, Lundin J (2003) Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 9(3): 923–930 - PubMed

MeSH terms